Literature DB >> 28267837

Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids.

Suzanne Nielsen1, Briony Larance1, Nicholas Lintzeris2.   

Abstract

Clinical Question: Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated with differences in efficacy for treating prescription opioid dependence, and is long-term maintenance of opioid agonist treatment associated with differences in efficacy compared with opioid taper or psychological treatments alone? Bottom Line: For patients who are dependent on prescription opioids, long-term maintenance of opioid agonists is associated with less prescription opioid use and better adherence to medication and psychological therapies for opioid dependence compared with opioid taper or psychological treatments alone. Methadone maintenance was not associated with differences in therapeutic efficacy compared with buprenorphine maintenance treatment. Evidence quality was low to moderate.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28267837     DOI: 10.1001/jama.2017.0001

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  14 in total

1.  Density of low-barrier opioid agonist clinics and risk of non-fatal overdose during a community-wide overdose crisis: A spatial analysis.

Authors:  Ofer Amram; Eugenia Socías; Ekaterina Nosova; Thomas Kerr; Evan Wood; Kora DeBeck; Kanna Hayashi; Nadia Fairbairn; Julio Montaner; M J Milloy
Journal:  Spat Spatiotemporal Epidemiol       Date:  2019-07-04

2.  Perceptions and practices addressing diversion among US buprenorphine prescribers.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Adam J Gordon; Hannah K Knudsen
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

3.  Comparing Buprenorphine-Prescribing Physicians Across Nonmetropolitan and Metropolitan Areas in the United States.

Authors:  Lewei Allison Lin; Hannah K Knudsen
Journal:  Ann Fam Med       Date:  2019-05       Impact factor: 5.166

4.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043

5.  Gender Differences in Patterns and Correlates of Continued Substance Use among Patients in Methadone Maintenance Treatment.

Authors:  Tomorrow D Arnold; Lewei Allison Lin; Brandi P Cotton; William C Bryson; Courtney A Polenick
Journal:  Subst Use Misuse       Date:  2021-03-01       Impact factor: 2.164

6.  Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Hannah K Knudsen
Journal:  Addict Behav       Date:  2019-01-16       Impact factor: 4.591

7.  Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis.

Authors:  Hannah K Knudsen; Lewei Allison Lin; Michelle R Lofwall
Journal:  Subst Abus       Date:  2019-07-11       Impact factor: 3.984

8.  Prevalence of Coaddictions and Rate of Successful Treatment Among a French Sample of Opioid-Dependent Patients With Long-Term Opioid Substitution Therapy: The OPAL Study.

Authors:  Marie Grall-Bronnec; Edouard-Jules Laforgue; Gaëlle Challet-Bouju; Jennyfer Cholet; Jean-Benoit Hardouin; Juliette Leboucher; Morgane Guillou-Landréat; Caroline Victorri-Vigneau
Journal:  Front Psychiatry       Date:  2019-10-17       Impact factor: 4.157

9.  Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder.

Authors:  Thuy Nguyen; Barbara Andraka-Christou; Kosali Simon; W David Bradford
Journal:  JAMA Netw Open       Date:  2019-12-02

10.  Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.

Authors:  Lewei A Lin; John C Fortney; Amy S B Bohnert; Lara N Coughlin; Lan Zhang; John D Piette
Journal:  J Subst Abuse Treat       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.